Pharmafile Logo

Cooleys Anemia Foundation

- PMLiVE

Gilead owes BMS millions after losing Yescarta patent infringement trial

Jury found Gilead's CAR-T infringed on exclusive patent

Bristol Myers Squibb logo

BMS’ oral maintenance therapy boosts survival in AML patients

Drug improved survival by almost ten months

- PMLiVE

Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

Late-stage candidate hit the mark in phase 3 study

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

- PMLiVE

Five key trends in precision and personalised healthcare

Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...

Blue Latitude Health

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

Celgene building

UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

Patient journey mapping: exploring the clinical and the emotional journey

By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew

Bristol Myers Squibb logo

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Group sales rose 6% to $6bn in the third quarter

Programmatic methodology and why you should be using it

What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director

Four Health

- PMLiVE

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

Regulatory filings expected in first half of 2020

- PMLiVE

How can we realise the benefits of patient engagement?

By Stephen O’Farrell and Nadine van Dongen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links